Pterygium Clinical Trial
Official title:
Efficacy and Safety of PRO-155 (Zebesten Ofteno®) on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
Title of the study Efficacy and safety of PRO-155 (Zebesten ofteno®) on inflammation of the
conjunctival surface in subjects with grade I-III pterygium vs placebo.
Hypothesis H0. The Zebesten® ophthalmic solution (bromfenac 0.09%) is less effective and safe
than placebo in reducing conjunctival hyperemia in subjects with grade I-III pterygium.
H1 The Zebesten® ophthalmic solution (bromfenac 0.09%) is more effective and safe than
placebo in reducing conjunctival hyperemia in subjects with grade I-III pterygium.
Objective
To evaluate the efficacy and safety of PRO-155 (bromfenac 009%) ophthalmic solution in the
treatment of conjunctival hyperemia and ocular surface inflammation in a clinical model of
pterygium grade I to III.
Variables to be evaluated Visual ability Intraocular pressure. Ocular surface Exploration of
the previous segment. Exploration of the posterior segment. Lacrimal rupture time. Corneal
de-epithelialization Conjunctival de-epithelialization Adverse events.
PHARMACOLOGICAL INTERVENTION
The pharmacological intervention will consist of the instillation of the ophthalmological
solution in the conjunctival cul-de-sac, during the waking period, to any of the following
study groups:
- Group 1:
- Sodium hyaluronate 0.4% [Lagricel ofteno®] 1 drop 3 times a day in the period of
vigil in the conjunctival sac fund (the following application scheme is suggested:
start: 7:00 ± 1 hours, continuation: 15:00 ± 1 hour and term: at 19:00 ± 1 hours)
for 20 days
- Pro-155 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
(the following application scheme is recommended: start: 7:15 ± 1 hours and term:
at 19:15 ± 1 hours) during 20 days
- Group 2:
- Sodium hyaluronate 0.4% [Lagricel ofteno®] 1 drop 3 times a day in the period of
vigil in the conjunctival sac fund (the following application scheme is suggested:
start: 7:00 ± 1 hours, continuation: 15:00 ± 1 hour and term: at 19:00 ± 1 hours)
for 20 days
- Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
(the following application scheme is recommended: start: 7:15 ± 1 hours and term:
at 19:15 ± 1 hours) for 20 days
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02641132 -
Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.
|
Phase 4 | |
| Completed |
NCT02342392 -
Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01387971 -
Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders
|
N/A | |
| Recruiting |
NCT05978687 -
The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision
|
Phase 4 | |
| Not yet recruiting |
NCT06042296 -
Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
|
||
| Completed |
NCT04022811 -
Effect of Bromfenac on Pain Related to Pterygium Surgery
|
Phase 4 | |
| Recruiting |
NCT01249235 -
Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery
|
N/A | |
| Recruiting |
NCT01261455 -
Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia
|
N/A | |
| Completed |
NCT01115517 -
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
|
Phase 2 | |
| Completed |
NCT00768963 -
Ranibizumab for the Inhibition of Neovascularization in Pterygia
|
Phase 1 | |
| Completed |
NCT00949728 -
Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia
|
N/A | |
| Recruiting |
NCT00563277 -
Surgical Treatment of Concurrent Cataract and Primary Pterygium
|
N/A | |
| Completed |
NCT00346450 -
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
|
Phase 3 | |
| Completed |
NCT03533244 -
A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
|
Phase 2 | |
| Completed |
NCT04403516 -
Dextenza in Pterygium Surgery
|
Phase 4 | |
| Recruiting |
NCT02911532 -
Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia
|
N/A | |
| Not yet recruiting |
NCT03304366 -
Corneal Changes With Pentacam Before and After Pterygium
|
N/A | |
| Unknown status |
NCT02015000 -
Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation
|
N/A | |
| Completed |
NCT00344201 -
Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery
|
Phase 1 | |
| Recruiting |
NCT00326560 -
Comparison of Glue With Sutures for Pterygium Surgery
|
Phase 3 |